OPKO Health, Inc.
HealthcareNASDAQ:OPK · NASDAQ Global Select
-$0.03 today
Vol 1.74M · Avg 2.58M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-17.8%
avg -9.5%
ROIC
-11.3%
avg -6.1%
ROA
-11.7%
avg -6.6%
Analysis
ROIC is currently the strongest return metric at -11.3% versus its period average of -6.1%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Phillip Frost | Chairman of the Board & CEO | $1.45M | — | 90 | $216.23M | 28.64% |
Jane H. Hsiao | Vice Chairman of the Board & Chief Technical Officer | $1.36M | — | 79 | $500,000.00 | 0.07% |
Elias Adam Zerhouni | President & Vice Chairman of the Board | $1.36M | — | 75 | $500,000.00 | 0.07% |
Steven D. Rubin | Executive Vice President of Administration & Director | $1.22M | — | 66 | $437,500.00 | 0.06% |
Adam E. Logal | Senior Vice President, Chief Financial Officer, Chief Accounting Officer & Treasurer | $1.19M | — | 48 | $437,500.00 | 0.06% |
Hans Berner | President of OPKO Health Iberoamerica | — | — | — | — | — |
Akhtar Ashfaq | Senior Vice President of Clinical Research & Development and Medical Affairs - Opko Renal | — | — | — | — | — |
Arie Gutman | President of API | — | — | 72 | — | — |
Damien Burke | Chief Executive Officer of EirGen Pharma | — | — | — | — | — |
Giovanni Abbadessa | Chief Medical Officer of ModeX | — | — | — | — | — |
Charles W. Bishop | Chief Executive Officer of OPKO Renal | — | — | 74 | — | — |
Gary J. Nabel | Chief Information Officer & Director | — | — | 71 | $437,500.00 | 0.06% |
John R. Mascola | Chief Scientific Officer of ModeX | — | — | — | $394,340.00 | 0.05% |
Craig Allen | Chief Executive Officer of Bioreference Health | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
35
$4.09M
Sells
0
$0.00
Net Sentiment
+$4.09M
Net buying
Most Active
FROST PHILLIP MD ET AL
34 transactions
1–10 of 35
Analysis
Insiders reported 35 buys worth $4.09M and 0 sells worth $0.00 over the last 12 months. That adds up to net buying of $4.09M. FROST PHILLIP MD ET AL was the most active insider with 34 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | +118.6% | +2.3% (15yr)1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Recent growth has been strongest in Revenue at +118.6% over three years. Forward estimates point to Revenue at +2.3% (15yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Dianthus Therapeutics, Inc.
NASDAQ:DNTH
$3.43B
Nektar Therapeutics
NASDAQ:NKTR
$1.16B
Tandem Diabetes Care, Inc.
NASDAQ:TNDM
$1.14B
Xencor, Inc.
NASDAQ:XNCR
$914.17M
Pacira BioSciences, Inc.
NASDAQ:PCRX
$904.31M
Personalis, Inc.
NASDAQ:PSNL
$851.63M
Sana Biotechnology, Inc.
NASDAQ:SANA
$745.82M
Oculis Holding AG
NASDAQ:OCS
$634.01M
Claritev Corporation
NYSE:CTEV
$526.61M
LifeMD, Inc.
NASDAQ:LFMD
$227.30M
Who manages OPK?
OPKO Health, Inc. (OPK) lists 14 active executives. The top listed executive is Adam E. Logal, Senior Vice President, Chief Financial Officer, Chief Accounting Officer & Treasurer.
Are OPK insiders buying or selling?
Recent insider activity shows net buying of $33.40M.
Explore More
Continue the stock analysis
Jump to another research area for this company.